New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
10:17 EDTRIG, MMYT, GCI, TEVA, LFL, EPD, RBC, JNPROn The Fly: Analyst Upgrade Summary
Enterprise Products (EPD) upgraded to Outperform from Neutral at Credit Suisse... Gannett (GCI) upgraded to Equal Weight from Underweight at Barclays... Juniper (JNPR) upgraded to Outperform from Market Perform at Wells Fargo... LATAM Airlines (LFL) upgraded to Strong Buy from Outperform at Raymond James... MakeMyTrip (MMYT) upgraded to Outperform from Perform at Oppenheimer... Regal-Beloit (RBC) upgraded to Outperform from Neutral at RW Baird... Teva (TEVA) upgraded to Neutral from Sell at Goldman... Transocean (RIG) upgraded to Neutral from Sell at Citigroup.
News For EPD;GCI;JNPR;LFL;MMYT;RBC;TEVA;RIG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
May 19, 2015
07:52 EDTEPDEnterprise Products initiated with a Buy at Wunderlich
Subscribe for More Information
07:31 EDTRIGUBS to hold a conference
Subscribe for More Information
06:08 EDTTEVAPerrigo CEO says would talk with Mylan, but at a higher price, Globes reports
Subscribe for More Information
May 18, 2015
16:56 EDTRIGTransocean provides fleet summary update
Transocean issued a monthly Fleet Update Summary, which includes new contracts, changes to existing contracts, and changes in estimated planned out-of-service time of 15 or more days since the April 16, 2015 Fleet Status Report. The total value of new contracts since the last report is approximately $52M. The report includes the following: GSF Development Driller II - Awarded a contract extension for approximately 100 days offshore Romania at a dayrate of $315,000 ($28M estimated backlog). GSF Rig 140 - Awarded a contract extension for approximately 120 days offshore India at a dayrate of $156,000 ($19M estimated backlog). Sedco Express - Awarded a contract extension for 18 days offshore Nigeria at a dayrate of $300,000 ($5M estimated backlog). The Transocean Marianas, GSF Celtic Sea, and M.G. Hulme, Jr. are idle. Estimated 2015 out-of-service time decreased by a net 27 days. As announced on May 7, 2015, the company has amended its construction contracts with Keppel FELS to further delay the delivery of its five newbuild high- specification jackups. This is in addition to the six-month delay announced in February 2015.
16:26 EDTEPDEnterprise Products initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:00 EDTRIGOptions Update; May 18, 2015
Subscribe for More Information
11:15 EDTRIGStocks with call strike movement; CHK RIG
Subscribe for More Information
May 15, 2015
17:33 EDTRBCPoint72 Asset Management gives quarterly update on stakes
Subscribe for More Information
17:08 EDTTEVASoros Fund gives quarterly update on stakes
Subscribe for More Information
16:31 EDTRIGTransocean declares dividend of 60c per share
Subscribe for More Information
10:45 EDTRIGStocks with call strike movement; CHK RIG
Chesapeake (CHK) October 17 call option implied volatility increased 2% to 45, Transocean (RIG) August 21 call option implied volatility increased 4% to 42 according to IVolatility.
09:31 EDTTEVAAmerican Thoracic Society to hold a conference
ATS 2015 Conference is being held in Denver on May 15-20.
08:12 EDTTEVATeva migraine treatment data positive, says Bernstein
Subscribe for More Information
08:04 EDTTEVATeva to present new respiratory data at 2015 ATS conference
Teva Pharmaceutical Industries announced that three company-sponsored abstracts will be presented at the 2015 American Thoracic Society International Conference in Denver, Colorado on May 15-19.Data to be presented include a Phase III study examining the functionality, reliability, accuracy and overall patient satisfaction of ProAir RespiClick inhalation powder, which gained approval from the U.S. FDA in March 2015. ProAir RespiClick is now available by prescription and is indicated for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. Additional Phase III data to be presented include a late-breaking abstract highlighting an interim analysis of the long-term safety and efficacy of Teva’s investigational anti-IL-5 therapy, reslizumab, in patients with asthma and elevated blood eosinophils. A third abstract to be presented includes data from a dose-ranging study of fluticasone propionate multi-dose, dry-powder inhaler in adolescent and adult patients with asthma.
07:37 EDTMMYTMakeMyTrip price target lowered to $25 from $35 at Deutsche Bank
Subscribe for More Information
07:19 EDTMMYTMakeMyTrip sees FY16 revenue less service costs growth of 22%-26%
Subscribe for More Information
07:16 EDTMMYTMakeMyTrip reports Q4 adjusted EPS (4c), consensus (3c)
Reports Q4 revenue less service costs $36.37M, consensus $39.92M. Gross Bookings reached $404.4M in Q4 and $1.65B in FY15, representing a year-over-year increase of 19.4% and 32.2% respectively. Results reported yesterday morning in a regulatory filing.
05:50 EDTRIGStocks with implied volatility movement; YOKU RIG
Subscribe for More Information
May 14, 2015
08:35 EDTTEVATeva says data present case for TEV-48125 progression to Phase III
Subscribe for More Information
07:44 EDTTEVAInternational Headache Society to hold a conference
17th Congress of the International Headache Society is being held in Valencia, Spain on May 14-17.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use